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Abstract
Background: APC (Adenomatous polyposis coli) plays an important role in the pathogenesis of
both familial and sporadic colorectal cancer. Patients carrying germline APC mutations develop
multiple colonic adenomas at younger age and higher frequency than non-carrier cases which
indicates that silencing of one APC allele may be sufficient to initiate the transformation process.
Methods: To elucidate the biological dysregulation underlying adenoma formation we examined
global gene expression profiles of adenomas and corresponding normal mucosa from an FAP
patient. Differential expression of the most significant gene identified in this study was further
validated by mRNA in situ hybridization, reverse transcriptase PCR and Northern blotting in different
sets of adenomas, tumours and cancer cell lines.
Results: Eighty four genes were differentially expressed between all adenomas and corresponding
normal mucosa, while only seven genes showed differential expression within the adenomas. The
first group included pregnancy specific β -1 glycoprotein 9 (PSG9) (p < 0.006). PSG9 is a member of
the carcinoembryonic antigen (CEA)/PSG family and is produced at high levels during pregnancy,
mainly by syncytiotrophoblasts. Further analysis of sporadic and familial colorectal cancer
confirmed that PSG9 is ectopically upregulated in vivo by cancer cells. In total, deregulation of PSG9
mRNA was detected in 78% (14/18) of FAP adenomas and 75% (45/60) of sporadic colorectal
cancer cases tested.
Conclusion: Detection of PSG9  expression in adenomas, and at higher levels in FAP cases,
indicates that germline APC mutations and defects in Wnt signalling modulate PSG9 expression.
Since PSG9 is not found in the non-pregnant adult except in association with cancer, and it appears
to be an early molecular event associated with colorectal cancer monitoring of its expression may
be useful as a biomarker for the early detection of this disease.
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Background
FAP is characterized by the development of hundreds to
thousands of adenomas throughout the entire colon and
rectum which, if left untreated, progress to colorectal can-
cer [1,2]. FAP, an inherited tumour predisposition, is
caused by mutant alleles of the adenomatous polyposis
coli (APC) gene and provides an opportunity to define
critical early genetic events in the development of
tumours [3]. Early development of a large number of
colon adenomas in this disorder indicates that mutations
in the APC gene can be rate-limiting in adenoma develop-
ment. The majority of colorectal tumours are sporadic in
origin, however, they exhibit close similarities to tumours
resulting in inherited colorectal cancer syndromes. Most
sporadic colon adenomas and carcinomas also harbour
APC gene mutations [4]. The APC gene, which has been
recognized as a gatekeeper of colorectal carcinogenesis, is
one of the key components of the Wnt signalling pathway.
Wnt signalling induces nuclear translocation of transcrip-
tionally active β -catenin through interference with the β -
catenin-destruction complex, composed of glycogen syn-
thase kinase-3 (GSK-3α  and β ), Axin (Axin1 and 2) and
APC. In the absence of a Wnt signal this complex effi-
ciently earmarks cytoplasmic β -catenin for degradation
through the ubiquitin/proteasome pathway [5,6].
To identify the possible differences between different ade-
nomas that either predispose to cancer or result in benign
growths, we compared variations in gene expression
between different adenomas and normal mucosa from
the same patient with a germline mutation in the APC
gene. The approach was designed to identify very early
changes that occur during adenoma formation and to
detect aberrant regulation of genes required for adenoma-
carcinoma progression. Microarray-based expression pro-
filing revealed that gene expression patterns between dif-
ferent adenomas are very similar but are different from
normal mucosa. We describe the increased expression of a
specific member of the pregnancy specific glycoprotein
family and show that induction of this gene is a very early
event that does not appear to be dependent on activation
of β -catenin.
Methods
Samples
Adenomatous polyps, tumours and matched adjacent
normal mucosal tissue samples from 18 FAP cases (germ-
line APC mutations detected by standard techniques), 60
sporadic colorectal cancer cases, five liver metastases and
one normal placenta, were obtained from University
Health Network (UHN) human tissue bank and the
Familial GI Cancer Registry at Mount Sinai hospital, in
compliance with each Institutional Review Board. Color-
ectal cancer cell lines; SW620, SW480, LoVo, RKO,
SW1417, LS1034 and MCF12A were purchased from
ATCC and grown in media recommended by the distribu-
tor. Total RNA samples from normal ovarian, prostate,
colon, breast and placental tissues were purchased from
Ambion and Clontech. RNA was extracted from cell lines
and tissue samples using an RNAeasy kit (Qiagen). Tissues
were processed for RNA extraction, in situ hybridization or
immunohistochemistry analysis.
Microarray procedure and data analysis
cDNA microarrays consisting of 19,200 human gene
clones were employed to explore the variation in gene
expression between adenoma and normal mucosa. Micro-
array slides were obtained from the University Health Net-
work Microarray Centre (UHN, Toronto, Canada).
Protocols used for array hybridisation were as published
on the UHN Microarray Centre web page http://
www.microarray.ca/support/proto.html with some modi-
fications. Briefly, 5 µg total RNA extracted from normal
mucosa or adenoma was labelled with Cy5 and, a refer-
ence total RNA pool was labelled with Cy3. The reference
RNA used was composed of total RNA from 10 human
cell lines (Stratagene) which hybridize to the maximum
number of spots on the array. The signals obtained from
reference RNA have been used for normalisation of exper-
imental samples. Microarray hybridization was carried
out in a hybridization chamber humidified with 2XSSC.
Labeled cDNA was dissolved in 80 µl of the hybridization
buffer, denatured at 95°C for three minutes in a thermal
cycler, and applied on the microarray slides. Microarrays
were incubated overnight at 37°C. Post-hybridization
washing was performed by serial incubations in buffers
with decreasing SSC and SDS concentrations, at 50°C. At
least two replicates including dye switches were per-
formed for each experiment to account for possible dye
labelling and hybridization bias. Relative expression was
assessed by a two-colour hybridization experiment. Slides
were scanned using either an Axon GenePix 4000A
(Axon) or ScanArray 4000 Scanner (Packard BioScience).
The scanned 16-bit TIFF images were quantified using
QuantArray software (Packard BioScience). The quanti-
fied data files were transferred to a GeneTraffic microarray
database and analysis system (Iobion Informatics, Strata-
gene) with a complete annotation of experiments based
on the current MIAME standards for microarray experi-
ments http://www.mged.org. Each hybridization dataset
was filtered and spots that did not pass the quality criteria
in both channels were excluded from further analysis. The
lowess subarray normalization which uses a local
weighted smoother to generate an intensity-dependent
normalisation function was applied to each hybridiza-
tion. The normalised log2 ratios were used for statistical
analysis. Data were analysed by both SAM software (Sig-
nificance Analysis for Microarrays) and the statistical pro-
gram integrated into GeneTraffic 2.8. Genes exhibiting aBMC Cancer 2005, 5:66 http://www.biomedcentral.com/1471-2407/5/66
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consistent 2-fold or more up- or down regulation with a p
value of <0.05 were considered significant.
Semi-quantitative and quantitative RT-PCR
Two µg total RNA was reverse transcribed by SuperScript
II reverse transcriptase (Stratagene). One µg of each cDNA
were amplified using PSG9 specific primers (PSG9-1420)
by AccuaPrime Taq DNA Polymerase system (Invitrogen)
(Fig. 1). For semi-quantitative PCR, all samples were nor-
malised to the level of glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) before PSG9 specific amplification.
For quantitative real-time PCR analyses, 500 ng cDNA was
amplified using a SYBR Green PCR kit and either primer
PSG9, GAPDH or Axin2 and a 7900 Sequence Detector
system (Applied Biosystems). Primers were designed by
either Oligo 6.4 (Oligo) or Primer Express software
(Applied Biosystems). Location of all primers for PSG9 are
indicated in figure 1a. Primer sequences used for semi-
quantitative PCR were as follow: PSG9-1420F (5'-CCA
GCC ACC CAA AGT TTC-3', PSG9-1420R (5'-GGG CAT
TCA GAT AGA CAG CAA-3'), GAPDH-F (5'-GAC GCC
TGC TTC ACC ACC TTC-3') and GAPDH-R (5'-CCG CTT
CGC TCT CTG CTC C-3'). Primers used for quantitative
RT-PCR were as follows: PSG9-Q40F (5'-TGG TGG CCT
CCG CAG TAA-3'), PSG9-Q40R (5'-GTC TGG ACC ATA
GAG GAC ATT TAG G-3'), GAPDH-F 5'-GAA GGT GAA
GGT CGG AGT C-3' and GAPDH-R 5'-GAA GAT GGT GAT
GGG ATT TC-3', Axin2F (5'-CCA CAC CCT TCT CCA ATC
CA-3') and Axin2R (5'-TGG ACA CCT GCC AGT TTC TTT-
3'). PCR conditions are available upon request.
Analysis of PSG9 sequence variants in tumors
PSG9 isoforms expressed in normal placenta, SW620 and
LoVo colon cancer cell lines and two sporadic colorectal
cancer cases, were PCR amplified. Different isoforms were
separated on a 2% agarose gel and purified by PerfectPrep
gel cleanup kit (Eppendorf). The purified DNA products
were cloned into pCR®II-TOPO vector. Clones were
sequenced in both directions using T7 and T3 primers
using an ABI sequencing system (Applied Biosystems).
Sequence variation was examined using GeneJockey II
software (Biosoft).
Northern blot analysis
PSG9  expression patterns were analysed using random
primed radiolabeled full-length PSG9 cDNA. A 2 kb frag-
ment was digested from a cDNA clone (GeneBank Acces-
sion No. 196828) by PAC I and EcoRI restriction
enzymes, gel purified and then radiolabeled with [α -
32P]dCTP using a T7 Quik Prime system (Pharmacia Bio-
tech). Northern blot analysis was performed based on
standard techniques [7].
RNA in situ hybridisation
RNA in situ hybridization (RISH) was used for the exami-
nation of PSG9 and PSG2 mRNA expression. Nonradioac-
tive RISH was applied to frozen or paraffin-embedded
sections using digoxigenin (DIG)-labelled copy RNA
(cRNA) probes. Different cDNA fragments corresponding
to human PSG9 (GenBank 196828) were amplified by
PCR using sense and antisense primers containing either
T7, T3 or SP6 promoter sequences, respectively. PSG2
riboprobes were amplified from a human placental RNA
pool (Clontech). The locations of primers and oligo-
probes sequences are indicated in figure 1. For cRNA
probe synthesis, purified PCR products were used. The
transcripts were labelled with DIG-labelled nucleotides,
DIG RNA labelling kit and either T7, T3 or SP6 RNA
polymerase (Roche Applied Science) to produce DIG-
labelled riboprobes. Primers used for amplification and
synthesis of each cRNA probe were: PSG9-E2; Sense 5'-T
GCC GAA GTC ACG ATT GAA G-3', Anti-sense: 5'-GGA
TGC GTT GGA ATA TAC TGT TTC T-3', PSG9-E4-5; Sense:
5'-A TGT CTT AGC CTT CAC CTG TG-3', Anti-sense: 5'-
AGT GCC GGT GGG TTA GAT T-3' PSG2; Sense: 5'-GTC
CAG ACC TCC CCA GAA T-3', Anti-sense 5'-AGG CTG
CTA TGT TGG ATT AAG GAG AG-3'. PCR conditions are
available upon request. Seven-µm-thick sections of paraf-
fin-embedded or fresh frozen tissue were cut, fixed in
1XPBS (phosphate-buffered saline) containing 4% para-
formaldehyde. A standard in situ hybridization technique
was used with some modifications. Images were analysed
by light microscope (Leica).
Western blot and immunohistochemical analysis
To detect β -catenin and β -actin, cells were lysed in RIPA
buffer (150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS,
50 mM Tris pH 8.0, 1 mM EDTA). Twenty µg protein were
loaded onto 8% SDS polyacrylamide gels, separated and
transferred to a nitrocellulose filter by semidry transfer.
Western blotting were performed using a standard proto-
col. The antibody dilutions were as follows; primary anti-
bodies β -catenin (1:1000; Transduction Laboratories) and
β -actin (1:2000; Abcam), secondary monoclonal anti-
body (1:5000; BioRad). Standard immunohistochemistry
(IHC) was carried out on formalin-fixed, paraffin-embed-
ded or fresh frozen sections.
Wnt signalling stimulation and reporter gene assay
RKO cells were treated over night with 50 nM Wnt3a
recombinant (R&D systems) or 10 µM Kenpaullone (Cal-
biochem) an inhibitor of GSK3 [8] prior to RNA or pro-
tein extraction. RKO cells transfection was performed in
six-well plates at the density of 1.5 × 105 cells/well with
Lipofectamine 2000 reagent (Invitrogen). Cells were
transfected with either Super8XTOP- or 8XFOPFlash and
β -galactosidase constructs [9] and were assayed for luci-
ferase activity 23 hrs post-transfection/treatment. TheBMC Cancer 2005, 5:66 http://www.biomedcentral.com/1471-2407/5/66
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Genomic structure of PSG9 Figure 1
Genomic structure of PSG9. The human PSG9 gene is located on chromosome 19q13.2 and encodes at least three variants. The 
exon structures of each isoform are indicated in the figure. The largest PSG9 variant, variant 1, consists of 1282 nucleotides 
and encodes for a protein of 427 amino acids. The location and size of each primer and riboprobes used in this study are indi-
cated (a). Statistical analysis of microarray data using SAM program revealed up to two-fold over-expression of PSG9 in ade-
noma 1, 2 and 3 (A1 to A3) compared to normal (N). The log2 ratio of fluorescence intensity is shown on the y-axis while PSG9 
expression in different samples is shown on the x-axis. At least four microarray replicates including dye switches (Cy3- or Cy5-
labelled) were performed to account for possible labeling and hybridization bias (b). The data have further been verified in ade-
noma 1, 2 and normal tissue by Real Time PCR (c).
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luciferase activity was measured and quantified in a lumi-
nometer using a chemiluminescent reporter gene assay
system for the combined detection of luciferase and β -
galactosidase as recommended by manufacturer (Applied
Biosystems). The β -galactosidase was used to normalize
luciferase units in each transfection.
Results
Gene expression profiling
Gene profiles of three adenomas and corresponding nor-
mal epithelial tissue from an FAP patient (case 640) with
an APC germline mutation (n. 2092; T→ G) were analysed
using 19K human cDNA microarray chips. Statistical anal-
ysis using SAM and GeneTraffic 2.8 revealed eighty four
transcripts to be represented at statistically significant dif-
ferent levels in all adenomas compared to normal (p <
0.05) (Table 1, 2, 3). Pregnancy specific β 1 glycoprotein 9
(PSG9) showed a consistent two fold up-regulation in
adenomas compared to normal mucosa and as the most
statistically significant candidate in these experiments (p
< 0.006) was selected for further analysis (Fig. 1b). The
result was consistent between all adenomas on all the
microarray chips tested. Differential PSG9 expression was
further verified using quantitative RT-PCR (Fig. 1c). PSG9
is a member of the pregnancy specific glycoprotein family
(PSGs) [10,11]. We also detected deregulation of a
number of TGFβ  (transforming growth factor β ) regulated
genes in our cDNA microarray gene expression screening.
Table 1: Genes upregulated in all adenomas compared to normal mucosa (p < 0.05).
Name Description Gene ID Fold change
PSG9 pregnancy specific beta-1-glycoprotein 9 196828 2.59
PPP2CB protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform 469697 1.71
ITGA1 integrin, alpha 1 212078 1.95
NEDD8 neural precursor cell expressed, developmentally down-regulated 8 220392 1.74
ALAS2 aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia) 201112 1.98
DCN decorin 197609 1.85
JAG1 jagged 1 (Alagille syndrome) 117734 2.21
DPP6 dipeptidylpeptidase 6 166550 1.86
RNASE4 ribonuclease, RNase A family, 4 201596 2.44
XBP1 X-box binding protein 1 213933 1.95
CDC42 cell division cycle 42 (GTP binding protein, 25 kDa) 214563 1.73
MGC8407 hypothetical protein MGC8407 179857 1.78
NUP98 nucleoporin 98 kDa 206345 2.02
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 470149 1.56
IL1R2 interleukin 1 receptor, type II 470402 1.54
PIP5K1B phosphatidylinositol-4-phosphate 5-kinase, type I, beta 211877 1.64
TAGLN2 transgelin 2 152371 1.67
TAF7 TAF7 RNA polymerase II, TATA box binding protein (TBP)-associated factor 365930 1.81
RAB25 RAB25, member RAS oncogene family 149515 1.64
ANAPC7 anaphase-promoting complex subunit 7 487822 1.79
MTCH2 mitochondrial carrier homolog 2 (C. elegans) 138486 1.8
HCA112 hepatocellular carcinoma-associated antigen 112 207556 2.3
BS69 adenovirus 5 E1A binding protein 31337 1.69
MGC29898 hypothetical protein MGC29898 504671 1.65
LOC124245 hypothetical protein BC001584 194780 2.05
FVT1 follicular lymphoma variant translocation 1 115784 1.55
FLJ20202 FLJ20202 protein 142952 1.59
ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 32555 1.63
HEAB ATP/GTP-binding protein 212684 1.59
VRK3 vaccinia related kinase 3 488478 1.49
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 200735 1.48
WFDC2 WAP four-disulfide core domain 2 366323 1.85
KIAA0241 KIAA0241 protein 212216 1.83
GPR161 G protein-coupled receptor 161 489796 1.81
SLAMF8 SLAM family member 8 128371 1.99
ARG99 ARG99 protein 163160 1.7
LOC170394 hypothetical protein BC011630 154928 1.9
Differentially expressed genes identified in adenomas compared to corresponding normal tissue. In total, 84 genes showed significant differential 
expression in all three adenomas compared to normal-appearing epithelial cells (p < 0.05). Thirty-seven genes were up-regulated (Table 1), and 47 
down-regulated (Table 2). PSG9 showed a consistent 2-fold over-expression in all adenomas compared to normal mucosa (p < 0.006).BMC Cancer 2005, 5:66 http://www.biomedcentral.com/1471-2407/5/66
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Similar to PSG9, TGFβ  plays an essential role in normal
placentation and is expressed by uterine epithelium from
early in pregnancy (Table 1 and 2).
PSG family member expression
Seventeen PSG clones are represented on the 19K human
chip used in these studies: four clones represent PSG1,
one for PSG3, two PSG4, two PSG5 clones, two PSG6,
three PSG11, and three clones are assigned as PSG9. To
examine why only one of the PSG9 clones on the cDNA
chip indicated differential expression between normal
mucosa and polyps, we re-sequenced all the clones repre-
senting PSG9. The sequencing results showed that only
clone 196828 contained a full-length PSG9 cDNA. This
Table 2: Genes downregulated in all adenomas compared to normal mucosa (p < 0.05).
Name Description Gene ID Fold change
AFP alpha-fetoprotein 428098 1.91
GFAP glial fibrillary acidic protein 382693 2.23
HBB hemoglobin, beta 148425 1.74
CLU clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2 343293 1.75
VDR vitamin D (1,25- dihydroxyvitamin D3) receptor 344295 2.09
MGP matrix Gla protein 502239 1.97
IGFBP2 insulin-like growth factor binding protein 2, 36 kDa 471830 1.74
PRKCE protein kinase C, epsilon 51986 3.39
COX4I1 cytochrome c oxidase subunit IV isoform 1 178644 1.89
APOB apolipoprotein B (including Ag(x) antigen) 300017 1.97
BIRC4 baculoviral IAP repeat-containing 4 138505 2.15
ITGAE integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide) 358848 2.3
GAS1 growth arrest-specific 1 341345 1.47
GATA3 GATA binding protein 3 148627 1.47
VEGFB vascular endothelial growth factor B 167296 2.01
ADIPOR2 adiponectin receptor 2 24286 1.98
RUFY2 RUN and FYVE domain containing 2 161523 2
LRP8 low density lipoprotein receptor-related protein 8, apolipoprotein e receptor 134714 2.1
SHMT2 serine hydroxymethyltransferase 2 (mitochondrial) 51583 1.96
TXK TXK tyrosine kinase 147839 1.7
LOC51315 hypothetical protein LOC51315 503300 1.39
UGCGL2 UDP-glucose ceramide glucosyltransferase-like 2 32716 3.02
MGC5178 hypothetical protein MGC5178 235090 1.73
IPO9 importin 9 233100 1.71
KBRAS2 I-kappa-B-interacting Ras-like protein 2 5091 2.05
SLC35F2 solute carrier family 35, member F2 42703 2.55
FLJ33761 hypothetical protein FLJ33761 23095 2.07
ZNF198 zinc finger protein 198 153735 1.75
PAG phosphoprotein associated with glycosphingolipid-enriched microdomains 487926 2
FLJ40432 hypothetical protein FLJ40432 23334 2.12
LOC114926 hypothetical protein BC013035 270038 1.64
LOC51277 Ras-associated protein Rap1 44081 1.92
FLJ20360 hypothetical protein FLJ20360 270110 1.61
LOC56931 hypothetical protein from EUROIMAGE 1967720 145011 1.8
LBP-32 leader-binding protein 32 195784 1.81
SATB2 SATB family member 2 26583 1.78
CTDSP1 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase 1 131828 2.13
OSBPL2 oxysterol binding protein-like 2 305402 1.81
FLJ38991 hypothetical protein FLJ38991 31673 2.16
MGC12972 hypothetical protein MGC12972 256553 1.69
ZNF496 zinc finger protein 496 32065 1.81
FLJ35936 hypothetical protein FLJ35936 33409 2
C14orf141 chromosome 14 open reading frame 141 161520 1.68
SGPP2 sphingosine-1-phosphate phosphotase 2 46316 1.94
DKFZp313N0621 hypothetical protein DKFZp313N0621 258616 2.22
LOC285550 hypothetical protein LOC285550 250675 1.89
MGC52498 hypothetical protein MGC52498 683068 1.85BMC Cancer 2005, 5:66 http://www.biomedcentral.com/1471-2407/5/66
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clone represents the largest transcript of PSG9. Because of
the high homology (>90%) between different PSG genes
and possible cross-hybridization and non-specific bind-
ing of primers to different PSGs and also to different tran-
scripts of PSG9, all primers were designed based on the
sequence of this clone (Fig. 1a).
Expression of PSG9 in normal and cancer cells
PSG isoforms were originally identified in the circulation
of pregnant women [12] and PSG concentrations in the
bloodstream increase exponentially until term. By the
third trimester the concentration reaches 200–400 µg/ml
[13]. Using monoclonal antibodies against PSG as a
group and studying their mRNA expression level, it was
shown that PSGs  are expressed mainly by
synthiotrophoblasts during pregnancy, while their expres-
sion in normal colon, could not be detected [14,15].
Other studies have reported that PSGs are not exclusively
expressed in human placenta and a number of PSG cDNA
clones have been isolated from fetal liver, salivary gland,
testis, myeloid cells and intestine [16-18]. However, the
expression level in these tissues appears to be very low.
Because anti-PSG antibodies used in some studies can
cross-react with other members of the CEA family, the
expression pattern and level of individual PSG proteins
and their variants is not well documented. Therefore, we
examined the normal expression pattern of PSG9 in differ-
ent tissues by using a multiple tissue northern blot, semi-
and quantitative RT-PCR. High expression of PSG9 tran-
scripts was detected in placenta after only few hours of
exposure, while expression in other tissues, including nor-
mal colon mucosa was undetectable even after one week
exposures (Fig 2a). This result was further verified by
quantitative RT-PCR analysis of PSG9 transcripts in differ-
ent normal tissues (Fig. 2b). PSG9 expression was also
examined in a panel of colorectal cancer cell lines. The
highest level of PSG9 was found in the SW480 cell line
which, similar to placental cells, expresses at least three
different PSG9 transcripts. The RKO colon cancer cell line
exhibited the lowest level of PSG9 (Fig. 2c–d). We also
examined the degree of PSG9 expression in a panel of
RNAs extracted from different tumours. Northern blot
analysis showed clear expression of three PSG9 transcripts
in colon and rectal cancer, and two transcripts in uterine
cancer (Fig. 3a). Primary sporadic colorectal tumours,
liver metastasis and corresponding normal tissues were
also examined for PSG9 expression by semi- and quanti-
tative PCR. Deregulation of PSG9 variants could be
detected in most tumours and liver metastases tested. Of
note, the expression pattern varied between different
tumours and also between different colon cancer cell
lines, which may relate to the stage of differentiation or
type of mutation in those cases (Fig. 3b). It is also possible
that the type of APC mutation plays a role in the level and
pattern of PSG9 transcription.
To determine the degree of PSG9 deregulation in colorec-
tal cancer we employed RNA in situ hybridization. Digox-
igenin (DIG)-labelled riboprobes were designed to
recognize specifically PSG9 variant 1 (nt 776→ 1087) or
all variants (nt 98→ 318) (Fig. 1a). Normal placental tis-
sues were used as positive control where both PSG9 and
another member of PSG family, PSG2  are highly
expressed (Fig. 4b–c). Sense-probes were used as negative
controls (Fig. 4a). PSG9 RNA transcripts were detected at
higher levels and at earlier stages in FAP cases than spo-
radic colorectal cancer. Transcripts of PSG9 were detected
in 78% (14/18) of adenomas from FAP cases with APC
germline mutations (Fig. 4g). Of those, 50% also
expressed  PSG9  in the corresponding normal mucosa
(Fig. 4d). However, the expression level was lower in the
histologically normal tissue than in the corresponding
adenomas and tumours (Fig. 4e–g). In all cases the expres-
sion level was much higher in tumours compared to cor-
responding normal mucosa or adenoma in FAP cases. The
degree of PSG9 expression in the tumour samples appears
Table 3: Genes differentially expressed within different adenomas compared to corresponding normal mucosa.
Gene's name Description A1 A2 A3
GAS1 growth arrest-specific 1 ↓↑↓
IGFBP2 insulin-like growth factor binding protein 2 ↓↑↓
MAPRE3 microtubule-associated protein, RP/EB family, member 3 ↑↓↓
ZFYVE20 zinc finger, FYVE domain containing 20 ↑↑↓
FLJ11848 hypothetical protein FLJ11848 ↓↓↑
KIAA1750 KIAA1750 protein ↓↓↑
KIAA1941 KIAA1941 protein ↓↑↓
Differentially expressed genes identified in adenomas compared to corresponding normal tissue. In total, 84 genes showed significant differential 
expression in all three adenomas compared to normal-appearing epithelial cells (p < 0.05). Thirty-seven genes were up-regulated (Table 1), and 47 
down-regulated (Table 2). PSG9 showed a consistent 2-fold over-expression in all adenomas compared to normal mucosa (p < 0.006).BMC Cancer 2005, 5:66 http://www.biomedcentral.com/1471-2407/5/66
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PSG9 is exclusively expressed by placental cells Figure 2
PSG9 is exclusively expressed by placental cells. Quantitative RT-PCR analysis of PSG9 transcript (a) and northern blot analysis of 
different normal tissues (1 µg mRNA/lane) probed with the labelled PSG9 cDNA (b) shows specific expression of PSG9 in pla-
centa. (a-b). Colorectal cancer cell lines were also examined for PSG9 expression level by quantitative- (c) and semi-quantita-
tive RT-PCR (d). Highest expression level of PSG9 was detected in SW480 cells and was lowest in the RKO cell line (c-d).
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to be related to differentiation, with highly differentiated
cells expressing the highest levels. PSG9 expression was
also detected in 70% (42/60) of sporadic colorectal can-
cers, while only 8% (5/60) of the corresponding normal
mucosa showed even low levels of PSG9 expression (Fig.
4i, 4k). To examine whether PSG9 expression was specific
for tumours, we examined expression of PSG2 in the same
tumours which had exhibited deregulated PSG9 expres-
PSG9 is ectopically expressed by cancer cells Figure 3
PSG9 is ectopically expressed by cancer cells. A multiple-tumour Northern blot (10 µg RNA/lane) revealed over-expression of 
PSG9 in colon, rectal and uterus cancer. At least three different transcripts were observed (a). Expression of PSG9 "isoform a" 
was examined in a panel of colorectal cancer cases. Forty-nine percent (15/27) of cases showed up-regulation of PSG9 (isoform 
a) in the tumours compared to corresponding normal tissue (b). However, the expression levels were different between differ-
ent cases (T; tumour, A; adenoma).
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RNA in situ hybridization and IHC analysis of colorectal cancer cases Figure 4
RNA in situ hybridization and IHC analysis of colorectal cancer cases. Sections from sporadic/familial colorectal cancer and placenta 
(as positive control) were hybridised with Dig-labelled PSG9 RNA probes. Both PSG2 (b) and PSG9 (c) were expressed at a 
high level in placental tissue. Sense-probes were used as a negative control on placental tissue (a). In microscopic normal epi-
thelial cells from FAP cases, PSG9 expression was detected at the top of crypt (d) (see discussion). PSG9 transcripts (shown as 
dark blue) were detected at very low levels in normal mucosa (e), adenomas (f), while high expression was detected in tumour 
cells from the same FAP case (g). In contrast to sporadic cases, PSG9 was detected in normal appearing mucosa in some FAP 
cases with APC germline mutations, suggesting that dose and level of APC have an impact on PSG9 levels in cells (e, i). A high 
level of PSG9 was detected in a sporadic case (k), while corresponding normal tissue was negative (i). Tumours and corre-
sponding normal tissue were also examined for β -catenin stabilization by immunostaining (h, j, l). As expected, high levels of β -
catenin were detected in all sporadic colorectal tumours (l), while the protein level was less intense in FAP cases (h) where 
PSG9 up-regulation could be measured (g).BMC Cancer 2005, 5:66 http://www.biomedcentral.com/1471-2407/5/66
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sion.  PSG2  was expressed at very low levels in both
tumour and normal mucosa from colorectal cancer cases.
As indicated earlier, both PSG9 and PSG2 are highly
expressed in placenta (Fig. 4b–c). In general, PSG9 could
be detected at higher levels in FAP cases. Notably, PSG9
was expressed in the morphologically normal mucosa of
FAP patients with APC germline mutations (Fig. 4d–e),
while its expression was rarely detectable in normal
mucosa of sporadic colorectal cancers using in situ hybrid-
ization (Fig. 4i). The expression pattern of PSG9 also var-
ied between different tumours and cell lines although the
significance of these differences is unclear (Fig. 2–4). Nor-
mal tissues, adenomas and tumours were also examined
for nuclear β -catenin accumulation by immunostaining
(Fig. 4h, j, l). Nuclear β -catenin could be detected in all
sporadic tumours (Fig. 4l), while staining was less intense
in the normal-appearing epithelium and adenomas in
FAP cases where PSG9 was highly upregulated (Fig. 4g–h).
In general, higher levels of β -catenin nuclear accumula-
tion could be detected in sporadic cancer (Fig 4l) com-
pared to FAP cases (Fig. 4h) while as expected no β -
catenin stabilisation was observed in the corresponding
normal tissues (Fig. 4j).
Next, we examined whether the PSG9  expressed in
tumours was different from PSG9 expressed by placental
cells during pregnancy. The coding sequences of all PSG9
variants of two colon cancer cell lines (SW620 and LoVo)
and two sporadic colorectal cancer cases were cloned and
sequenced. Two sequence variations were found in the
non-coding region, while no changes were found in the
coding region of PSG9. These results indicate that the
PSG9 proteins expressed by placental cells and tumour
cells have similar sequences and might have similar func-
tion, however, the level of expression of each PSG9 variant
differed from those found in placenta.
Effect of Wnt signal activation on PSG9 expression in the 
absence of APC mutation
Nuclear localization of β -catenin has been shown to cor-
relate with its transcriptional activity in cells. While
SW480 cells with very high levels of β -catenin and APC
mutations express high levels of PSG9, RKO cells which
have previously been reported to express wild type APC
and β -catenin [19,20] show no PSG9 expression (Fig. 2c
and 5a–b). To investigate the potential role of β -catenin/
Wnt3a up-regulation in the absence of APC mutations on
PSG9 transcription, accumulation and nuclear localiza-
tion of β -catenin in RKO cells was induced by treatment
with recombinant Wnt3a, Kenpaullone, or using a stable
RKO-β -catenin cell line which expresses constitutively a
active mutant (β cat-S37A) form of β -catenin [21] (Fig.
5b). One day post-treatment, cells were prepared for luci-
ferase assays and RNA extraction. Reporter gene assays
were performed to examine the ability of these cells to
respond to Wnt stimulation and quantitative PCR to
investigate whether Axin2, a known Wnt signal down-
stream target gene was induced. Stimulation of the cells
resulted in four-fold induction of luciferase activity (Fig.
5c), and a 2.4-fold increase in Axin2 transcript levels, indi-
cating that these cells are able to respond to Wnt signaling
and this signal induction can increase downstream target
gene expression (Fig. 5d). We further examined the PSG9
expression level in these stimulated cells. No PSG9 induc-
tion in these cells could be detected (Fig. 5e). These results
suggest that enhanced levels of β -catenin or Wnt signaling
in cells, without concomitant defect in APC, is likely
insufficient to induce PSG9 expression.
Discussion
In this study, we have shown that PSG9 is ectopically
expressed in colorectal cancer and this is most likely APC
dependent, since abnormal expression can be detected as
early as in normal appearing epithelial cells and adeno-
mas of the FAP cases which carry APC germline mutations,
while corresponding normal tissue in sporadic colorectal
cancer tumors lack PSG9 expression. Given the increased
expression of PSG9 in the mucosal cells of FAP patients
that displayed lower β -catenin stabilisation compared to
sporadic colorectal tumours in our study, it is possible
that PSG9 is not directly regulated by the β -catenin/Wnt
signalling pathway and that other molecules that regulate
PSG9  expression are altered as a consequence of APC
mutation. Notably, deregulation of PSG9 is detectable as
early as in mucosa that appears histologically normal in
FAP cases with APC germline mutations, suggesting that
the dose and gradient of APC is important in PSG9
regulation. Functional analysis of APC protein has
revealed a broad spectrum of activities for this molecule
[22,23]. In normal-appearing epithelial cells in FAP, PSG9
was expressed mostly on the apical surface, while in
tumours, expression was detected from the top to the base
of crypts. Early expression of PSG9 even before adenoma
formation at the top of the crypts in FAP cases, suggests
that transformation process starts in cells at the top of the
crypts which then gradually move downward (Fig. 4d).
These observations are consistent with the "top-down"
morphogenesis model of colorectal cancer [24].
PSGs exhibit sequence similarity to the carcinoembryonic
antigen (CEA) family which, in turn, is a member of the
immunoglobulin (Ig) superfamily. The CEA gene family
can be divided into three subgroups; the CEA subgroup
(12 genes), PSG subgroup (11 genes) and a pseudogene
subgroup (6 genes) [25]. CEA is a widely used tumour
marker, the main clinical utility of which is in monitoring
clinical course of colorectal carcinoma after surgical resec-
tion [26]. Contrary to its name, CEA is expressed in nor-
mal adult tissue, as well as during fetal development. The
role of CEA in normal human physiology is not wellBMC Cancer 2005, 5:66 http://www.biomedcentral.com/1471-2407/5/66
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PSG9 expression analysis in Wnt stimulated RKO cells Figure 5
PSG9 expression analysis in Wnt stimulated RKO cells. To determine whether induction of Wnt signaling in cells with wild type 
APC could induce PSG9 expression, RKO cells with wild type APC and β -catenin were stimulated with either Wnt3a or Ken-
paullone (Kenp). After 23 hrs treatment RNA and protein were extracted and processed for PSG9 transcripts expression level 
by semi-quantitative RT-PCR (a) and β -catenin accumulation by western blot analysis (b). Neither of the treatments nor the 
RKO-β -cateninS37A (β cat-S37A) stable cell line which expressed constitutively active β -catenin in RKO cells caused expression 
of PSG9 (a). The SW480 colorectal cancer cell line was used as a positive control (a-b). The RKO cells responded to Wnt stim-
ulation, since cells treated with Wnt3a showed 4-fold induction in luciferase activity compared to untreated cells (c). Axin2, a 
known downstream target of Wnt signaling, showed 2.4 fold up-regulation in expression as determined by quantitative PCR 
(d). No PSG9 transcript up-regulation was detected in these cells under these conditions (e). Each sample was analyzed in 
triplicate.
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understood. Based on its structure, a number of functions
have been suggested, including intracellular cell adhesion,
signal transduction or signal transduction regulation.
PSGs are secreted proteins and, in contrast to CEA, most
PSGs are not expressed in normal colon epithelial cells.
The main site for PSG production is the placental syncyti-
otrophoblasts during pregnancy [14]. Although PSGs
were discovered more than three decades ago, their func-
tion is still unknown and the receptor(s) for these pro-
teins has yet to be identified. Most PSGs have an RGD
(Arg-Gly-Asp) motif in a conserved region in the N-termi-
nal domain which suggest that these genes may function
as adhesion recognition signals for integrins [27].
Immune privilege of cancer cells
Several studies suggest that T-cells are capable of recogniz-
ing and responding to tumours in experimental condi-
tions, yet most tumours are able to escape detection by the
immune system. A common characteristic of cancer and
the placenta is their ability to avoid immune reactivity.
The capability of cancer cells to sidestep the body's
immune reaction, is believed to be partly aided by the
protective coating of the cells, which is largely composed
of glycoproteins [28]. PSGs are heavily glycosylated pro-
teins and the primary amino acid sequence is masked by
the sugar modification which helps in avoid specific anti-
body recognition [29]. It has been suggested that PSG pro-
duction by trophoblasts regulates maternal immune
response to the fetus. It is also possible that PSG9
expressed by pre-malignant and cancer cells protect
tumours from recognition by the body's immune
defences. Another similarity between the respective milieu
where both placenta and adenomas develop is their low-
oxygen environment. Trophoblast invasion and placental
development during the first trimester occurs in a low-
oxygen environment, as the blood flow to the intervillous
space is not yet established [30]. We found lower levels of
beta hemoglobin (HBB) RNA in adenomas compared to
normal mucosa in this study (Table 1) as well as in
another gene profiling study we have performed (manu-
script in preparation).
Role of PSG9 in cancer
Most of the PSG subgroup (11 genes) are expressed. How-
ever, the existence of allelic variants with a stop codon in
the N-domain of some PSGs, indicates that some individ-
uals may not express all members of the PSG family [31].
The possible involvement of PSGs in cancer and their
genetic variation may in part explain phenotypic diver-
gence that exists in cancer cases with otherwise identical
germline mutations. The RGD sequence motif in the N-
terminal domain of most PSGs is also present in a variety
of extracellular matrix proteins that bind to integrin recep-
tors such as fibronectin and vitronectin [32]. It has been
hypothesized that the PSGs (like most Ig superfamily
members) are involved in adhesion/recognition proc-
esses. Another possibility is that upregulation of PSG9
might favour tumour development by causing a reversion
of the monolayered adult colonic epithelium to an
embryonic multilayered arrangement.
Conclusion
Our results provide strong evidence that PSG9 deregula-
tion in cells occurs early during adenoma-carcinoma for-
mation. High levels and early deregulation of PSG9 in
adenomas, as well as normal mucosa in some FAP cases,
indicates the potent role of APC germline mutations that
are often found in these cases. The precise role of PSG9 in
carcinogenesis remains to be determined. However, early-
onset over-expression of PSG9 in different types of cancer
suggests that this gene may be considered as a valuable
biochemical tumorigenesis marker. To elucidate whether
the frequency of occurrence of elevated PSG9 could have
clinical significance, further analysis of serum levels of
PSG9 and also other PSGs are warranted. Since PSG9 is
not found in the non-pregnant adult except in association
with cancer, it may be useful as a biomarker for the early
detection of cancers of various types.
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